retatrutide 1 month results PDB-101: Molecule of the Month: GLP-1 Receptor Agonists Lilly's triple agonist, retatrutide, delivered

Only eight of the studies were with the new GLP-1 medications (semaglutide and tirzepatide)

Understanding what happens each week prevents unnecessary discontinuation during the hardest period

Many companies state that their products are 99% pure, but an independent investigation of three companies products from August 2023 to March 2024 found that the purity of the products were far less than promised

This is reassuring

Its been said to: strengthen gut lining, protect from metabolic inflammation, improve metabolic profile, and decrease insulin resistance

Although both pharmacological approaches target GLP-1, important differences exist concerning the mode of administration (subcutaneous injection versus oral ingestion), the efficacy (better with GLP-1 agonists), the effects on body weight and systolic blood pressure (diminution with agonists versus neutrality with gliptins), the tolerance profile (nausea and possibly vomiting with agonists) and the cost (higher with GLP-1 receptor agonists)